CHICAGO (EGMN) - Nothing less than a revolution in the management of refractory thyroid cancer is close at hand in the form of oral small molecule tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor, according to speakers at the annual meeting of the American Thyroid Association."There's not a question in my mind that this is going to be a very important therapeutic intervention," said Dr. Samuel A. Wells Jr., professor of surgery at Washington University, St. Louis. "This...